Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 8/2012

01-08-2012 | Letter

ADVANCE and glycaemia thresholds: a need to clarify the statistical approach

Author: C. J. Currie

Published in: Diabetologia | Issue 8/2012

Login to get access

Excerpt

To the Editor: The recent study published by the ADVANCE Collaborative Group confirming that there is a lower threshold of optimal HbA1c [1] is a welcome confirmation of the original work published in The Lancet [2]. However, there is at least one important analytical failing that simply must be addressed for this study to be considered valid. Furthermore, the authors’ analysis may violate an assumption of the survival methods that were applied in the original study. …
Literature
1.
Zoungas S, Chalmers J, Ninomiya T et al (2012) Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 55:636–643PubMedCrossRef
2.
Currie CJ, Peters JR, Tynan A et al (2010) Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 375:481–489PubMedCrossRef
3.
ADVANCE Collaborative Group, Patel A, MacMahon S et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572PubMedCrossRef
4.
Sehra D, Sehra S, Sehra ST (2011) Sulfonylureas: do we need to introspect safety again? Expert Opin Drug Saf 10:851–861PubMedCrossRef
5.
Currie CJ, Johnson JA (2012) The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes Obes Metab 14:1–4PubMedCrossRef
6.
Clayton D, Hills M (1993) Time changing explanatory variables. In: Statistical models in epidemiology. Oxford University Press, Oxford, pp 307–318
Metadata
Title
ADVANCE and glycaemia thresholds: a need to clarify the statistical approach
Author
C. J. Currie
Publication date
01-08-2012
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 8/2012
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-012-2575-4

Other articles of this Issue 8/2012

Diabetologia 8/2012 Go to the issue

Article

Long-term mortality in patients with type 2 diabetes undergoing coronary angiography: the impact of glucose-lowering treatment

Short Communication

Trends in childhood type 1 diabetes incidence in Europe during 1989–2008: evidence of non-uniformity over time in rates of increase

Letter

ADVANCE and glycaemia thresholds: a need to clarify the statistical approach. Reply to Currie CJ [letter]

Short Communication

HbA1c variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2

Article

High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes

Article

Central nervous system endoplasmic reticulum stress in a murine model of type 2 diabetes
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits